New Onset Generalized Pustular Psoriasis Rapidly Improved with IL-36 Blockade

Generalized pustular psoriasis is a relatively rare variant of psoriasis characterized by diffuse eruption of sterile pustules on an erythematous background. Untreated flares can result in life-threatening complications including sepsis and organ failure. Generalized pustular psoriasis has historica...

Full description

Saved in:
Bibliographic Details
Published in:Skin (Milwood, N.Y.) N.Y.), 2023-01, Vol.7 (1), p.585-588
Main Authors: Burns, Meredith, Orlowski, Timothy, Ho-Pham, Hoang, Elston, Carly, Elewski, Boni
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Generalized pustular psoriasis is a relatively rare variant of psoriasis characterized by diffuse eruption of sterile pustules on an erythematous background. Untreated flares can result in life-threatening complications including sepsis and organ failure. Generalized pustular psoriasis has historically proven challenging to treat with an unpredictable clinical course and paucity of reliably efficacious treatment options. Until recently, there have been no FDA-approved therapies for generalized pustular psoriasis in the United States. In September 2022, the IL-36 receptor antagonist spesolimab became the first FDA-approved treatment for generalized pustular psoriasis in adults. We present a case of generalized pustular psoriasis with complete and rapid response to spesolimab.
ISSN:2574-1624
2574-1624
DOI:10.25251/skin.7.1.4